The Non Alcoholic Fatty Liver Strategy™ By Julissa Clay the program discussed in the eBook, Non Alcoholic Fatty Liver Strategy, has been designed to improve the health of your liver just by eliminating the factors and reversing the effects caused by your fatty liver. It has been made an easy-to-follow program by breaking it up into lists of recipes and stepwise instructions. Everyone can use this clinically proven program without any risk. You can claim your money back within 60 days if its results are not appealing to you.
What is the prevalence of fatty liver in patients with psoriasis, supported by comorbidity data, and how do biologic therapies for psoriasis compare with lifestyle modification in liver outcomes?
Yes, there is a very high prevalence of fatty liver disease in patients with psoriasis, supported by extensive comorbidity data showing a two- to three-fold increased risk compared to the general population. While biologic therapies for psoriasis, particularly TNF-alpha inhibitors, can improve liver outcomes by reducing the systemic inflammation that drives both diseases, intensive lifestyle modification remains the most effective and essential treatment for the fatty liver component itself. The two approaches are complementary, not competitive, with lifestyle changes addressing the root metabolic cause of the liver disease.
📈 The High Prevalence of Fatty Liver in Psoriasis
Psoriasis is now understood to be far more than a skin-deep condition; it is a chronic, systemic inflammatory disease that significantly increases the risk of numerous other health problems. Among the most common and concerning of these is non-alcoholic fatty liver disease (NAFLD). Large-scale studies and meta-analyses have consistently demonstrated a strong link between the two conditions. The data reveal that the prevalence of NAFLD in patients with psoriasis is strikingly high, estimated to be between 40% and 70%, depending on the population and the diagnostic methods used. This is more than double the rate seen in the general population. Furthermore, the risk is not uniform; it correlates directly with the severity of the skin disease. Patients with more severe, extensive psoriasis are more likely to have more advanced forms of liver disease, including non-alcoholic steatohepatitis (NASH), which involves liver inflammation and can progress to cirrhosis.
🤝 Shared Pathways: The Inflammatory Link
The connection between a skin disease and a liver disease is rooted in a shared underlying pathology: chronic systemic inflammation. Psoriasis is driven by an overactive immune system that releases a cascade of pro-inflammatory signaling molecules called cytokines into the bloodstream. Key among these are Tumor Necrosis Factor-alpha (TNF-α), Interleukin-17 (IL-17), and Interleukin-23 (IL-23). These are the same cytokines that cause the rapid skin cell turnover and plaque formation seen in psoriasis.
Crucially, these circulating cytokines also travel to the liver, where they wreak havoc on its metabolic functions. They are known to directly promote insulin resistance, a condition where the body’s cells don’t respond properly to the hormone insulin. This leads to higher blood sugar levels and, importantly, it signals the liver to ramp up its production of fat (de novo lipogenesis). This newly created fat accumulates in the liver cells, causing steatosis. These inflammatory molecules also directly promote inflammation within the liver itself, helping to drive the progression from simple fatty liver to the more dangerous NASH. This shared inflammatory pathway is further compounded by the high prevalence of metabolic syndrome in psoriasis patients. Psoriasis, metabolic syndrome (the cluster of obesity, high blood pressure, diabetes, and abnormal cholesterol), and NAFLD form a tightly interconnected and dangerous triad.
💊 Biologics vs. Lifestyle: A Comparison of Liver Outcomes 🌿
When managing a patient with both psoriasis and fatty liver, clinicians must consider the effects of their interventions on both the skin and the liver.
Biologic Therapies for Psoriasis
Biologic drugs are highly targeted treatments that work by blocking specific inflammatory cytokines. Their effect on the liver is largely beneficial and is a direct consequence of their mechanism of action.
- TNF-α inhibitors (e.g., adalimumab, etanercept, infliximab): Since TNF-α is a primary driver of both skin inflammation in psoriasis and liver inflammation and insulin resistance in NAFLD, blocking it is a “win-win.” Multiple studies have shown that psoriasis patients treated with TNF-α inhibitors often experience a significant improvement in their liver health. This is evidenced by a reduction in elevated liver enzymes (like ALT and AST) and, in some cases, improvements in markers of liver fibrosis and steatosis on imaging. By calming the systemic inflammatory storm, these drugs can indirectly treat the inflammatory component of the liver disease.
- IL-17 and IL-23 Inhibitors (e.g., secukinumab, ustekinumab): These newer biologics also work by reducing systemic inflammation. While the data is still emerging compared to the extensive research on TNF-α inhibitors, the principle is the same. By lowering the overall inflammatory burden, they are generally considered to have a neutral to beneficial effect on NAFLD, making them a safe choice for these patients.
Lifestyle Modification
While biologics offer a secondary benefit to the liver, intensive lifestyle modification is the primary, direct, and most effective treatment for NAFLD itself. There is currently no approved medication for fatty liver disease, making lifestyle changes the cornerstone of management. This involves:
- Weight Loss: Losing just 7-10% of one’s body weight has been proven to resolve steatohepatitis (liver inflammation) and can even reverse liver fibrosis in a significant number of patients.
- Dietary Changes: Adopting a diet rich in fruits, vegetables, and whole grains, such as the Mediterranean diet, while reducing the intake of processed foods, sugars, and saturated fats is critical.
- Regular Exercise: A combination of aerobic and resistance training improves insulin sensitivity and helps the body utilize fat for energy.
The Comparison
The two approaches are not mutually exclusive; in fact, they are highly complementary. Biologics treat the psoriasis and the shared inflammatory drive, while lifestyle modification treats the underlying metabolic dysfunction that is the root cause of the fatty liver. A biologic agent can reduce the inflammation that is aggravating the liver, but it cannot reverse the effects of a poor diet or sedentary lifestyle. Therefore, the optimal strategy for a patient with psoriasis and NAFLD is a dual approach: effective biologic therapy to control the skin disease and its systemic inflammation, combined with a dedicated and sustained effort at lifestyle modification to directly treat the fatty liver.
The Non Alcoholic Fatty Liver Strategy™ By Julissa Clay the program discussed in the eBook, Non Alcoholic Fatty Liver Strategy, has been designed to improve the health of your liver just by eliminating the factors and reversing the effects caused by your fatty liver. It has been made an easy-to-follow program by breaking it up into lists of recipes and stepwise instructions. Everyone can use this clinically proven program without any risk. You can claim your money back within 60 days if its results are not appealing to you
I’m Mr.Hotsia, sharing 30 years of travel experiences with readers worldwide. This review is based on my personal journey and what I’ve learned along the way. Learn more |